Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead128
Abstract: OBJECTIVES There is no consensus on canakinumab treatment tapering and discontinuation strategies in colchicine-resistant familial Mediterranean fever (FMF) patients. In this study, we aimed to establish a treatment management and discontinuation protocol in pediatric FMF… read more here.
Keywords: fmf patients; familial mediterranean; resistant familial; colchicine resistant ... See more keywords
A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead242
Abstract: OBJECTIVES Colchicine forms the mainstay of treatment in familial Mediterranean fever (FMF). Around 5-10% of FMF patients are colchicine resistant and require anti-interleukin-1 drugs. We aimed to compare the characteristics of colchicine-resistant and colchicine-responsive patients… read more here.
Keywords: diagnosis; colchicine resistant; colchicine; colchicine resistance ... See more keywords
An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000018328
Abstract: Abstract Background: Colchicine is the first-line treatment for familial Mediterranean fever (FMF), but secondary amyloidosis resulting from persistent inflammation is a concern in patients with colchicine-resistant or colchicine-intolerant FMF. Although tocilizumab (TCZ), which is a… read more here.
Keywords: resistant colchicine; colchicine; familial mediterranean; colchicine resistant ... See more keywords
Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-218901
Abstract: We read with great interest the article “Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial” by Ozen et al .1 This article… read more here.
Keywords: resistant familial; familial mediterranean; patients colchicine; mediterranean fever ... See more keywords
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Preventive Cardiology"
DOI: 10.1177/2047487319879534
Abstract: Aims Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with anakinra may be beneficial. The aim of this multicentre registry was to evaluate… read more here.
Keywords: dependent colchicine; corticosteroid dependent; anakinra; pericarditis ... See more keywords